MISSISSAUGA, ON, June 7, 2016 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI) a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that at its 2016 Annual Meeting of Shareholders held in Toronto, all nominees listed in the management proxy circular dated May 4, 2016 were elected as directors of the Company.
The detailed results of the votes by proxy are as follows:
Director Nominees | NUMBER OF SHARES | PERCENTAGE OF VOTES CAST | ||
FOR | WITHHELD | FOR | WITHHELD | |
Daniel Chicoine | 3,977,783 | 46,583 | 98.84% | 1.16% |
David A. Copeland | 3,916,886 | 107,480 | 97.33% | 2.67% |
Anthony E. Dobranowski | 3,917,205 | 107,161 | 97.34% | 2.66% |
John C. London | 3,982,114 | 42,252 | 98.95% | 1.05% |
Dr. Jacques Messier | 3,985,773 | 38,593 | 99.04% | 0.96% |
Samira Sakhia | 3,987,856 | 36,510 | 99.09% | 0.91% |
About Nuvo Pharmaceuticals Inc.
Nuvo (TSX:NRI) is a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities. Nuvo has three commercial products that are available in a number of countries; Pennsaid 2%, Pennsaid and the heated lidocaine/tetracaine patch. Pennsaid 2% is sold in the U.S. by Horizon Pharma plc (NASDAQ:HZNP) and is available for partnering in certain other territories around the world. Nuvo manufactures Pennsaid for the global market and Pennsaid 2% for the U.S. market at its FDA, Health Canada and EU approved manufacturing facility in Varennes, Québec. For additional information, please visit www.nuvopharmaceuticals.com.
SOURCE Nuvo Pharmaceuticals Inc.
